A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

Diverse subsets of endothelial progenitor cells (EPCs) are used for the treatment of ischemic
diseases in clinical trials, and circulating EPCs levels are considered as biomarkers for …

Context Clinical trial results suggest that intracoronary delivery of autologous bone marrow
mononuclear cells (BMCs) may improve left ventricular (LV) function when administered …

Cardiac fibroblasts are emerging as key components of normal cardiac function, as well as
the response to stressors and injury. These most numerous cells of the heart interact with …

Cardiac scars, often dubbed 'dead tissue', are very much alive, with heterocellular activity
contributing to the maintenance of structural and mechanical integrity following heart injury …

Myocardial infarction is associated with persistent muscle damage, scar formation and
depressed cardiac performance. Recent studies have demonstrated the clinical significance …

ContextExperimental studies and early phase clinical trials suggest that transplantation of
blood-derived or bone marrow–derived stem cells may improve cardiac regeneration and …

Background and Purpose—Endothelial progenitor cells (EPCs) migrate from bone marrow
to systemic circulation in response to tissue ischemia where they differentiate into mature …

• Introduction• Dynamics between endothelial injury and repair: the response to injury theory
'revisited'• Emerging biomarkers reflecting the dynamics between endothelial injury and …

Aims/hypothesis A reduction in the number of endothelial progenitor cells (EPCs) is
considered a plausible cause of increased cardiovascular risk in diabetes mellitus. The aim …